share_log
Reuters ·  08/19 09:00

Tuhura Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for Vista-101 Clinical Trial Evaluating Kva12123 in Patients With Advanced Solid Tumor Cancer

Tuhura Biosciences和kintara therapeutics宣布Kineta公司重新开放招募参与高级实体瘤癌患者评估kva12123的Vista-101临床试验

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发